PGEN vs RARE · rev $9.7M vs rev $350.0M
Precigen Inc (PGEN) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Precigen Inc (PGEN) is a biotechnology company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported PGEN revenue for 2025-12-31 was $9.7M. Net income was -$250.6M. PGEN currently screens at market cap $419.2M.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
PGEN currently screens at market cap $419.2M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the PGEN and RARE stock pages for the full models.
Not investment advice.